Genitourinary Cancer News

It has been exactly 40 years since Richard M. Fox, MB, PhD, FRACP; Tatiana Jelihovsky, MBBS, DCP, FRCPA, FRCPath; and I published our paper on genetic anticipation in germ cell malignancy.

The addition of maintenance avelumab to best supportive care extended OS for patients with previously untreated locally advanced or metastatic urothelial carcinoma, according to study results released by the agent’s manufacturer.

The FDA approved pembrolizumab for treatment of certain patients with bacillus Calmette-Guérin-unresponsive, high-risk nonmuscle-invasive bladder cancer.

Cancer mortality rates dropped by 29% between 1991 and 2017 in the United States, with a 2.2% drop between 2016 and 2017, according to according to data from Cancer Statistics 2020, American Cancer Society’s annual report on cancer rates and trends.

The FDA expanded the clearance of a cryoablation technology platform for the treatment of cancerous and benign tumors of the kidney; liver; and ear, nose or throat, according to a press release from the product’s manufacturer.

Patients who survived cancer have an increased risk for mortality from CHD and stroke compared with the general population, according to a study published in the European Heart Journal.

MicroRNAs — small noncoding RNAs that seem to be involved in epigenetic control of gene expression — have garnered increasing attention as potential biomarkers in the past few years, with interest focused on gastrointestinal malignancy, and now germ cell tumors.

The FDA granted priority review to UGN-101 as a potential treatment for patients with low-grade upper tract urothelial cancer, the agent’s manufacturer announced in a press release.

The FDA granted accelerated approval to enfortumab vedotin-ejfv for treatment of adults with locally advanced or metastatic urothelial cancer, the agent’s developers announced in a press release.

An FDA advisory committee today voted to support approval of pembrolizumab for the treatment of patients with bacillus Calmette-Guérin-unresponsive, high-risk, nonmuscle-invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.